Pregnancy is a hypercoagulable state, conferring an increased risk of venous thromboembolism (VTE). However, treatment algorithms for deep venous thrombosis and pulmonary embolism are based on studies of nonpregnant patients.
Methods:
A literature review of cases in which thrombolysis was used for the treatment of VTE during pregnancy was conducted using the PubMed (National Institutes of Health) database.
Results:
A PubMed database search of English language articles for reports of thrombolysis for the treatment of VTE in pregnancy identified 215 cases, including 183 cases of systemic thrombolysis, 19 cases of catheter-directed thrombolysis, and 13 cases of mechanical thrombectomy. For systemic thrombolysis, the maternal complication rate was 4.40% and the fetal complication rate was 1.65%. For catheter-directed thrombolysis, the maternal complication rate was 14.75% and the fetal complication rate was 5.2%. In cases of mechanical thrombectomy, there were no reported maternal or fetal complications.
Conclusions:
Although conservative strategies are preferred in pregnancy, thrombolysis is an adjunct for limb or life-threatening VTE. Review of past reports suggests low rates of maternal and fetal complications following systemic thrombolysis and mechanical thrombectomy but higher rates of complications after catheter-directed thrombolysis in the treatment of VTE during pregnancy.
HeitJAKobbervigCEJamesAHPettersonTMBaileyKRMeltonLJ3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706.
RomualdiEDentaliFRancanE. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal. J Thromb Haemost. 2013;11(2):270–281.
4.
PompELenselinkARosendaalFDoggenCJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632–637.
5.
EndenTHaigYKløwNE; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012;379(9810):31–38.
6.
MewissenMWSeabrookGRMeissnerMHCynamonJLabropoulosNHaughtonSH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 1999;211(1):39–49.
7.
PriscoDCiutiGFalcianiM, eds. Hemostatic changes in normal pregnancy. Hematology Meeting Reports (formerly Haematologica Reports). 2009. Page Press.
8.
AlexanderBMeyersLKennyJGoldsteinRGurewichVGrinspoonL. Blood coagulation in pregnancy: proconvertin and prothrombin, and the hypercoagulable state. N Engl J Med. 1956;254(8):358–363.
9.
WrightJCooperPAstedtB. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol. 1988;69(2):253–258.
10.
RagusaAPisoniMPWetzlRGMaccarioLCresciniC, eds. Maternal mortality and thromboembolic risk in pregnancy. Hematology Meeting Reports (formerly Haematologica Reports). 2009. Page Press.
11.
HeylPSSappenfieldWMBurchDHernandezLEKavanaughVMHillWC. Pregnancy-related deaths due to pulmonary embolism: findings from two state-based mortality reviews. Matern Child Health J. 2013;17(7):1230–1235.
12.
MarikPEPlanteLA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008;359(19):2025–2033.
13.
SimcoxLEOrmesherLTowerCGreerIA. Pulmonary thrombo-embolism in pregnancy: diagnosis and management. Breathe (Sheff). 2015;11(4):282–289.
14.
KlokFVan der HulleTDen ExterPLankeitMHuismanMKonstantinidesS. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev. 2014;28(6):221–226.
TickLKramerMRosendaalFFaberWDoggenCJ. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost. 2008;6(12):2075–2081.
17.
RobertsLNPatelRKDonaldsonNBonnerLAryaR. Post-thrombotic syndrome is an independent determinant of health-related quality of life following both first proximal and distal deep vein thrombosis. Haematologica. 2014;99(3):e41–e43.
18.
SansonBJFriederichPWSimioniP. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996;75(3):387–388.
19.
LindqvistPGSvenssonPJDahlbäckBMarsùálK. Factor VQ 506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss—a possible evolutionary selection mechanism. Thromb Haemost. 1998;79(1):69–73.
20.
SchulmanSAngeråsUBergqvistDErikssonBLassenMFisherW; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–204.
21.
BatesSMGreerIAMiddeldorpSVeenstraDLPrabulosAMVandvikPO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e691S–e736S.
22.
Nelson-PiercyCPowrieRBorgJY. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):293–299.
23.
HullRDTownshendG. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. Thromb Haemost. 2013;110(1):14–22.
24.
PettiläVLeinonenPMarkkolaAHiilesmaaVKaajaR. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87(2):182–186.
25.
MartelNLeeJWellsPS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710–2715.
26.
GouldMKDembitzerADDoyleRLHastieTJGarberAM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130(10):800–809.
27.
QuinlanDJMcQuillanAEikelboomJW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140(3):175–183.
28.
HassounaAAllamH. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact Cardiovasc Thorac Surg. 2014;18(6):797–806.
29.
WongVChengCHChanKC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. Am J Med Genet. 1993;45(1):17–21.
ValadaresSSerranoFTorresRBorgesA. Inferior vena cava filter placement during pregnancy: an adjuvant option when medical therapy fails. Case Rep Obstet Gynecol. 2013;2013:821635.
36.
SelimMHMolinaCA. The use of tissue plasminogen-activator in pregnancy: a taboo treatment or a time to think out of the box. Stroke. 2013;44(3):868–869.
37.
GartmanEJ. The use of thrombolytic therapy in pregnancy. Obstet Med. 2013;6(3):105–111. 10.1177/1753495X13488771.
38.
ShepardTHLemireRJ. Catalog of Teratogenic Agents: Johns Hopkins University Press; 2004.
39.
BivardALinLParsonsbMW. Review of stroke thrombolytics. J Stroke. 2013;15(2):90–98.
40.
AhearnGSHadjiliadisDGovertJATapsonVF. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. Arch Intern Med. 2002;162(11):1221–1227.
41.
LeonhardtGGaulCNietschHHBuerkeMSchleussnerE. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. 2006;21(3):271–276.
42.
PfeiferGW. The use of thrombolytic therapy in obstetrics and gynaecology. Australas Ann Med. 1970;19(suppl 1):28–31.
43.
HallRJYoungCSuttonGCCambellS. Treatment of acute massive pulmonary embolism by streptokinase during labour and delivery. Br Med J. 1972;4(5841):647–649.
44.
LudwigH. Results of streptokinase therapy in deep venous thrombosis during pregnancy. Postgraduate Med J. 1973;49:65–7.
45.
McTaggartDRIngramTG. Massive pulmonary embolism during pregnancy treated with streptokinase. Med J Aust. 1977;1(1-2):18–20.
46.
LudwigHGenzH, eds. Thrombolytic Treatment During Pregnancy. Thrombosis And Haemostasis. Stuttgart, Germany: Fk Schattauer Verlag; 1981.
47.
DelclosGLDavilaF. Thrombolytic therapy for pulmonary embolism in pregnancy: a case report. Am J Obstet Gynecol. 1986;155(2):375–376.
48.
FagherBAhlgrenMAstedtB. Acute massive pulmonary embolism treated with streptokinase during labor and the early puerperium. Acta Obstet Gynecol Scand. 1990;69(7-8):659–661.
49.
BaudoFCaimiTRedaelliR. Emergency treatment with recombinant tissue plasminogen activator of pulmonary embolism in a pregnant woman with antithrombin III deficiency. Am J Obstet Gynecol. 1990;163(4):1274–1275.
50.
FlossdorfTBreulmannMHopfHB. Successful treatment of massive pulmonary embolism with recombinant tissue type plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labour. Intensive Care Med. 1990;16(7):454–456.
51.
MazeikaPKOakleyCM. Massive pulmonary embolism in pregnancy treated with streptokinase and percutaneous catheter fragmentation. Eur Heart J. 1994;15(9):1281–1283.
52.
KramerWBBelfortMSaadeGRSuraniSMoiseKJ. Successful urokinase treatment of massive pulmonary embolism in pregnancy. Obstet Gynecol. 1995;86(4):660–662.
53.
La ValleurJMolinaEWilliamsPPRolnickSJ. Use of urokinase in pregnancy. Two success stories. Postgrad Med. 1996;99(5):269–270, 272–273.
54.
GrandAGhadbanWPerretSP. Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman. Ann Cardiol Angeiol (Paris). 1996;45(9):517–522.
55.
HuangWHKirzDSGalleeRCGordeyK. First trimester use of recombinant tissue plasminogen activator in pulmonary embolism. Obstet Gynecol. 2000;96(5 pt 2):838.
56.
HenrichWSchmiderAHenrichMDudenhausenJW. Acute iliac vein thrombosis in pregnancy treated successfully by streptokinase lysis: a case report. J Perinat Med. 2001;29(2):155–157.
57.
YapLBAlpNJForfarJC. Thrombolysis for acute massive pulmonary embolism during pregnancy. Int J Cardiol. 2002;82(2):193–194.
58.
BeebeejaunMYAdenugbaO. Use of thrombolytic agents to treat pulmonary embolism in pregnancy. Rev Obstet Gynecol. 2013;6(3-4):182–184.
59.
PatelRKFasanOAryaR. Thrombolysis in pregnancy. Thromb Haemost. 2003;90(6):1216–1217.
60.
TrukhachevaEScharffMGardnerMLakkisN. Massive pulmonary embolism in pregnancy treated with tissue plasminogen activator. Obstet Gynecol. 2005;106(5 Pt 2):1156–1158.
61.
BitekerMDuranNEOzkanM. Successful treatment of massive pulmonary embolism in a pregnant woman, with low-dose, slow infusion of tissue plasminogen activator. Turk Kardiyol Dern Ars. 2010;38(1):32–34.
62.
te RaaGDRibbertLSSnijderRJBiesmaDH. Treatment options in massive pulmonary embolism during pregnancy; a case-report and review of literature. Thromb Res. 2009;124(1):1–5.
63.
FasulloSMaringhiniGTerrazzinoGGanciFPaternaSDi PasqualeP. Thrombolysis for massive pulmonary embolism in pregnancy: a case report. Int J Emerg Med. 2011;4:69.
64.
LonjaretLLairezOGalinierMMinvilleV. Thrombolysis by recombinant tissue plasminogen activator during pregnancy: a case of massive pulmonary embolism. Am J Emerg Med. 2011;29(6):694.e1-e2.
65.
HoldenELRanuHShethAShannonMSMaddenBP. Thrombolysis for massive pulmonary embolism in pregnancy—a report of three cases and follow up over a two year period. Thromb Res. 2011;127(1):58–59.
66.
HaigYEndenTGrøttaO; CaVenT Study GroupPost-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016;3(2):e64–e71.
67.
VedanthamSGoldhaberSZJulianJA. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240–2252.
68.
KearonCAklEAOrnelasJ. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
69.
KrishnamurthyPMartinCBKayHH. Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option. J Matern Fetal Med. 1999;8(1):24–27.
70.
SofocleousCTHinrichsCBahramipourPBaroneAAbujudehHContractorD. Percutaneous management of life-threatening pulmonary embolism complicating early pregnancy. J Vasc Interv Radiol. 2001;12(11):1355–1356.
71.
BechtelJJMountfordMCEllinwoodWE. Massive pulmonary embolism in pregnancy treated with catheter fragmentation and local thrombolysis. Obstet Gynecol. 2005;106(5 pt 2):1158–1160.
72.
HerreraSComerotaAJThakurS. Managing iliofemoral deep venous thrombosis of pregnancy with a strategy of thrombus removal is safe and avoids post-thrombotic morbidity. J Vasc Surg. 2014;59(2):456–464.
73.
PickJBerlinDHorowitzJWinokurRSistaAKLichtmanAD. Massive pulmonary embolism in pregnancy treated with catheter-directed tissue plasminogen activator. A A Case Rep. 2015;4(7):91–94.
74.
BloomAIFarkasAKalishYElchalalUSpectreG. Pharmacomechanical catheter-directed thrombolysis for pregnancy-related iliofemoral deep vein thrombosis. J Vasc Interv Radiol. 2015;26(7):992–1000.
75.
O’KeeffeSMcGrathARyanJByrneB. Management of a massive pulmonary embolism in a pregnant patient with mechanical fragmentation followed by delayed catheter-directed thrombolysis in the early postpartum period. J Matern Fetal Neonatal Med. 2008;21(8):591–594.
76.
DeStephanoCCWernerEFHollyBPLessneML. Diagnosis and management of iliac vein thrombosis in pregnancy resulting from May-Thurner syndrome. J Perinatol. 2014;34(7):566–568.
77.
GedikogluMOguzkurtL. Endovascular treatment of iliofemoral deep vein thrombosis in pregnancy using US-guided percutaneous aspiration thrombectomy. Diagn Interv Radiol. 2017;23(1):71–76.
78.
Food and Drug Administration. ACTIVASE (alteplase) for injection [package insert]; 2015.
79.
AshraniAAHeitJA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009;28(4):465–476.
